Protein synthesis is dysregulated in many diseases, but we lack a systems-level picture of how signaling 26 molecules and RNA binding proteins interact with the translational machinery, largely due to 27 technological limitations. Here we present riboPLATE-seq, a scalable method for generating paired 28 libraries of ribosome-associated and total mRNA. As an extension of the PLATE-seq protocol, riboPLATE-29 seq utilizes barcoded primers for pooled library preparation, but additionally leverages rRNA 30 immunoprecipitation on whole polysomes to measure ribosome association (RA). We demonstrate the 31 performance of riboPLATE-seq and its utility in detecting translational alterations induced by inhibition 32 of protein kinases. 33 34 KEYWORDS 35 RNA-seq, translation, ribosome, immunoprecipitation, mTOR, MNK 36 37 BACKGROUND 38
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introducing sample-specific barcodes during reverse transcription to enable pooling of cDNA from 71 multiple individual samples at an early stage of library preparation, reducing both reagent and labor 72 costs. Furthermore, as PLATE-seq generates cDNA fragments strictly from the 3' ends of intact, 73 polyadenylated RNA via oligo-dT pulldown and priming, the resulting libraries saturate more rapidly 74 than those with full gene body coverage. Consequently, PLATE-seq is advantageous over conventional 75 RNA-seq in throughput of both library preparation and sequencing. 76
We take advantage of riboPLATE-seq for parallel, genome-wide translational profiling in 96 samples, 77 which would be technically challenging with conventional polysome or ribosome profiling. riboPLATE-78 seq uses pan-ribosomal immunoprecipitation to isolate the ribosome-associated fraction of each species 79 of polyadenylated transcript, enabling inferences regarding gene-specific translation akin to polysome 80 profiling. Using PLATE-seq as a readout for ribosomal IP, riboPLATE-seq enables high-throughput 81 translational profiling and screening of potential translational regulators. While riboPLATE-seq measures 82 the abundance of ribosome-bound mRNA rather than nucleotide-resolved ribosome density (as in 83 ribosome profiling), it is highly scalable, inexpensive, and seamlessly compatible with automated liquid 84 handling. 85
In this study, we use riboPLATE-seq to interrogate translational regulation mediated by the 86 PI3K/Akt/mTOR and MAPK/ERK signaling pathways. By treating cells with inhibitory drugs targeting 87 mTOR, PI3K, and MNK1 in a multi-well plate, we sought to uncover specific per-gene signatures of 88 altered translation corresponding to loss of function in these kinases. Additionally, we tested pairwise 89 combinations of these inhibitors to characterize their potential interactions. We also generated 90 signatures of mTOR and MNK1 inhibition in ribosome profiling and RNA sequencing for comparison to 91 established methods of interrogating translation. Importantly, ribosome profiling provides a measure of 92 ribosome-mRNA association that is quantitatively distinct from that of riboPLATE-seq. The ratio of 93 aligned reads in ribosome profiling over aligned reads in RNA-seq libraries obtained from the same 94 5 biological sample corresponds to the average number of ribosomes bound per individual transcript. In 95 contrast, the ratio of aligned reads in riboPLATE-seq over normal PLATE-seq corresponds instead to the 96 fraction of the total transcribed pool of transcripts bound by ribosomes. 97 98 RESULTS 99 riboPLATE-seq Technology 100 riboPLATE-seq enables transcriptome-wide measurements of ribosome association in a multi-well plate 101 format by combining pan-ribosomal immunoprecipitation (IP) with a low-cost technique for RNA-seq 102 called PLATE-seq ( Figure 1A) . In PLATE-seq, we isolate polyadenylated RNA species with an oligo-d(T) 103 capture plate, followed by incorporation of a well-specific barcode in poly(T)-primed reverse 104 transcription. After mixing the barcoded cDNA libraries from each well of a plate, we conduct all 105 subsequent library preparation steps on a single, pooled sample and sequence the resulting libraries to a 106 modest depth (~4 million reads per well). Previous studies have used ribosome IP to isolate ribosome-107 bound mRNA from specific cell types in vivo with the translating ribosome affinity purification (TRAP) 11 108 and RiboTag 6 systems, relying on transgenic or recombination-driven epitope labeling of ribosomal 109 proteins. In riboPLATE-seq, we use a native epitope in the 5.8S rRNA for pan-ribosomal IP. By comparing 110 transcript abundance as measured by PLATE-seq both with and without ribosomal IP, we can measure 111 gene-specific ribosome association across the transcriptome. In this way, riboPLATE-seq can extend the 112 scalability of PLATE-seq from transcriptional to translational profiling. 113
To implement riboPLATE-seq, we divide polysome lysates from a multi-well plate experiment into two 114 plates. We then subject one plate to indirect, pan-ribosomal IP on an automated liquid handling system 115 with biotinylated anti-rRNA antibody y10b and streptavidin-coated magnetic beads. Finally, we generate 116 PLATE-seq libraries from the immunoprecipitated polysomes from the first plate and total lysate from 117 6 the second plate as described previously. This design minimizes sample-to-sample noise due to batch 118 effects by processing an entire plate as one batch, and simultaneous processing of a plate via automated 119 liquid handling systems significantly reduces the time and effort required for processing large numbers 120 of samples. Furthermore, per-sample reagent costs are substantially lower in PLATE-based library 121 preparations. PLATE-seq generates 3'-end RNA libraries for under $6 per sample in reagents, while 122 riboPLATE-seq requires additional expenses for automated ribosome IP totaling ~$7 per sample for 123 reagents and disposables, all in 96-well plate format. A full riboPLATE-seq study performed on one 96-124 well plate costs less than $20 in materials per sample to generate paired libraries of ribosome-125 associated and total RNA, compared with $86 for ligation-free ribosome profiling and RNA sequencing. 126
riboPLATE-seq Translational Profiling Screen 127
To characterize the performance of riboPLATE-seq, we designed an experiment to identify the 128 translational impact of inhibiting multiple components of mitogenic signaling in cancer cells. TS-543 129 glioma neurospheres harbor an activating mutation in PDGFRA, leading to increased mitogenic signaling 130 activity 12 that exacerbates the effects of inhibiting these pathways. We treated cells seeded in a 96-well 131 plate with inhibitors of the PI3K/Akt/mTOR and MAPK/ERK signaling axes for six hours ( Figure 1B ), as 132 both pathways converge on the ribosome at eIF4E and are thought to influence the formation of the 133 eIF4F complex. This complex, formed from the cap-binding protein eIF4E, the RNA helicase eIF4A, and 134 the scaffold protein eIF4G, is required for cap-dependent translation initiation, and the association of 135 eIF4E and eIF4G is a heavily regulated component of this process. PI3K activates AKT which 136 phosphorylates mTOR, and activated mTOR facilitates eIF4F formation by phosphorylation of eIF4E-137 interacting proteins (4E-BPs), which then release eIF4E 1,2 . Separately, the MAPK signaling cascade 138 activates MNK1, which phosphorylates eIF4E directly, increasing its affinity for the 5' m7G cap and 139 stabilizing eIF4F 13 . By screening several members of these two pathways we sought to identify targets 140 specific to each individual member and compare translational signatures between pathways. The drug 141 7 treatments in total consisted of two competitive mTOR inhibitors, PP242 and AZD-8055; an inhibitor of 142 PI3K upstream of mTOR, BKM120; a specific inhibitor of MNK1/2 activity, MNK-i1; and 4EGi-1, a 4E-BP 143 mimic that inhibits the association of eIF4E and eIF4G. We determined concentrations of these drugs 144 from an examination of the literature, ensuring values near the half-maximum inhibitory concentrations 145 (IC50) for the main substrates of the drugs in question: 625nM PP242 14 , 50nM AZD-8055 15 , 1μM 146 BKM120 16 , 100nM MNK-i1 17 , and 50μM 4EGi-1 18 . In order to analyze possible interactions between 147 kinases, we also treated samples with pairwise combinations of PP242, BKM120, and MNK-i1. 148
Previous studies of the effect of MAP kinase interacting kinases (MKNKs, a.k.a. MNKs 1/2) on 149 translational regulation utilized small-molecule inhibitors of these proteins, notably the compound 150 CGP57380 19,20 . However, this compound has been shown to be a nonspecific inhibitor of several 151 unrelated kinases, with effects on eIF4F formation independent of its effects on MNKs. CGP57380 has 152 low-micromolar IC50 values for MNK isoforms (0.87 μM/ 1.6μM for MNK1/MNK2, respectively) and 153 significantly inhibits other kinases at these concentrations, including MKK1, CK1, and BRSK2 21 . 154
Additionally, CGP57380 concentrations below that which affects eIF4E phosphorylation may still 155 decrease proliferation and survival, and an increase in eIF4E:4EBP binding occurs at concentrations 156 below those impacting MNK1, indicating broad off-target effects impinging translational regulation 22 . 157 Determination of the translational targets of MNK1 via ribosome or polysome profiling with this drug in 158 prior work is complicated by this lack of specificity, especially with regards to off-target effects directly 159 impacting translational machinery. In contrast, MNK-i1 has been recently identified as a highly specific 160 MNK inhibitor, with IC50 values of 0.023 μM and 0.016 μM for MNK1 and MNK2 respectively, and blocks 161 eIF4E phosphorylation without impacting other pathways converging on eIF4E 22 . We therefore sought to 162 clarify the effect of MNK1 on translation with this novel inhibitor. 163 8 For comparison, we performed ribosome profiling and RNA-seq on TS-543 neurospheres treated with 164 PP242 or MNK-i1 in identical regimens to the riboPLATE-seq study, in order to assess the similarity of 165 translational perturbations detected across experiment types. As riboPLATE-seq measures the fraction 166 of an expressed transcript associated with ribosomes (hereafter referred to as "ribosome association" or 167 RA) and ribosome profiling/RNA-seq measure the average number of ribosomes bound per transcript 168 (conventionally defined as "translation efficiency" or TE), we expected these two methods to give 169 quantitatively distinct results while identifying similar sets of targets for these translational regulators. To assess the depletion of spike-in RNA in riboPLATE-seq, we added polyadenylated RNA standards 201 (ERCC spike-ins) to half of the wells in a riboPLATE-seq experiment, after lysis but prior to ribosome IP. 202 Figure 2D shows the distribution of the log2-ratio of spike-in abundance in riboPLATE-seq to PLATE-seq, 203 demonstrating depletion of spike-ins associated with ribosomal IP across most wells. The wells exhibit a 204 median 4.5-fold depletion ratio, and 31/48 wells exhibit 4-fold depletion or greater. However, two wells 205 exhibit a modest (<2-fold) enrichment of spike-ins after ribosome IP, and the wide distribution of 206 depletion log2-ratios ranges from 11 to 0.7 (equivalent to ~1.6-fold relative enrichment). Aside from 207 potential non-specific pulldown of spike-ins, random re-initiation of free ribosomes on polyadenylated 208 transcripts in lysate could result in their capture by ribosome immunoprecipitation, resulting in their 209 enrichment in riboPLATE-seq. This might be minimized in future riboPLATE-seq studies by inclusion of 210 GDPNP in the lysis buffer. As GTP hydrolysis is required in both start site selection and subunit joining 211 steps of 80S initiation complex formation, inclusion of a non-hydrolyzable GTP analogue such as GDPNP 212 would prevent re-initiation of free ribosomes in lysate 23 . In summary, inclusion of ERCC RNA spike-ins 213 provides a valuable, internal quality control measurement to check IP fidelity in riboPLATE-seq. 214
As ribosome profiling has revealed low but significant levels of ribosome occupancy among ncRNA 24 , we 215 sought to contrast ribosome association between ncRNA and mRNA transcripts with riboPLATE-seq. We 216 expected noncoding transcripts to be generally depleted in our riboPLATE-seq libraries compared with 217 PLATE-seq libraries from the same samples. Indeed, we observed lower RA for the set of highly-218 expressed ncRNA transcripts than mRNA within the same sample ( Figure 2E ). Examining the relationship 219 between RA and transcript abundance across ncRNA and mRNA gene sets also uncovered lower RAs for 220 ncRNA than mRNA at all expression levels ( Figure 2F) , with similar patterns observed between 221 translation efficiency (TE) and expression level in our ribosome profiling and RNA-seq data ( Figure 2G ). 222
Combined with the observed spike-in depletion, our results are consistent with the depletion of RNA 223 that is not bound to ribosomes by the pan-ribosomal immunoprecipitation implemented in riboPLATE-224 seq. 225
Pharmacological Screening of Mitogenic Signaling with riboPLATE-seq 226
After establishing the performance of the riboPLATE-seq, we sought to characterize its ability to detect 227 differential expression and RA. In principal component analyses (PCA) of the PLATE-seq and riboPLATE-228 seq profiles, samples segregate according to the drug with which they were treated and related drugs 229 co-cluster ( Figure 3A This division between strong and weak inhibitors also appears in the RA-dependent plots in Figure 3C (4EGi-1, MNK-i1/BKM120, PP242/MNK-i1, PP242/BKM120; Spearman rank correlation p=0.0) ( Table 2) . 251
riboPLATE-seq Differential Translation Efficiency Analysis 252
In order to more rigorously analyze differential ribosome association as a function of drug treatment, we 253 utilized DESeq2 to compare the replicates for each drug treatment to vehicle controls. We first identified 254 12 the total set of significantly differentially ribosome-associated genes across all singular drug treatments 255 and generated a hierarchically-clustered heatmap of differential RA across conditions ( Figure 4A ). 256
Signatures of differential RA due to treatment with PP242 (mTOR inhibitor), AZD8055 (mTOR inhibitor), 257 and BKM120 (PI3K inhibitor), which target the PI3K/mTOR pathway, form a cluster in the column 258 dendrogram. As expected, MNK-i1 and 4EGi-1 targets cluster separately. MNK-i1 targets MNK1 in a 259 separate pathway converging on the ribosome at eIF4E, and 4EGi-1 is a broad inhibitor of eIF4E and cap-260 dependent translation in general. 261
The closely related differential-RA signatures for PP242, BKM120, and AZD8055 also include strong 262 downregulation of the 5'TOP motif-containing genes, canonical translational targets of mTOR signaling, 263 as indicated by the black tick marks in Figure 4A . In the rightmost two columns of Figure 4A , signatures 264 of differential translation efficiency obtained via ribosome profiling and RNA-seq recapitulate the major 265 patterns seen in differential RA. Both up-and down-regulated targets of PP242 are in good agreement 266 between the two methods. The 5'TOP motif-containing genes exhibit low TE by ribosome profiling after 267 PP242 treatment, whereas MNKi-1 treatment is far less effective on these genes based on ribosome 268 profiling and leads to fewer differentially translated genes in general, consistent with riboPLATE-seq. 269
We used gene set enrichment analysis (GSEA) to identify gene ontologies associated with differential 270 ribosome association under each drug treatment ( Fig. 4B ), based on effect size of RA change associated 271 with each drug. Across all drugs, all ontologies with low family-wise error rate (FWER<0.001) have 272 negative normalized enrichment scores (NES), indicating a predominately inhibitory effect of these drugs 273 on ribosome association. All treatments downregulate genes related to translation initiation and 274 ribosomal components, as expected for inhibition of translation-activating signaling pathways. MNK-i1 275 treatment inhibits these ontologies despite a relatively weak effect on the TOP motif-containing genes, 276 suggestive of mTOR-independent inhibition of translation. Surprisingly, all kinase-dependent treatments 277 13 exhibit stronger, more consistent downregulation(s) of these genes than 4EGi-1; as this drug targets 278 eIF4E directly, we expected TOP genes to be included in the set of its strongly-inhibited targets. 279
Attenuation of Perturbations to Ribosome Association in Drug Combinations 280
We expected that drug combinations would elicit greater changes in RA than the individual drug 281 treatments alone. Specifically, we expected at least additivity if not outright synergy from simultaneous 282 inhibition of the PI3K/Akt/mTOR and MAPK/ERK pathways, and a similar but perhaps less pronounced 283 additivity of effects from inhibiting kinases in the same pathway (i.e. mTOR and PI3K). Surprisingly, we 284 instead found a pattern of attenuation of the strongest effects of individual drugs when combined. 285 Supplementary Table 1) . 297
Motif-Based Target Classification in a Translation Control Network 298
Finally, we displayed the results of our study in network form and mapped occurrences of a known 299 translational cis-regulatory element, the 5' TOP motif, across this network. Following the observation of 300 14 concordant regulation of canonical TOP genes in drug treatments impacting the mTOR signaling 301 pathway, we first sought to expand the potential set of TOP genes within the strongly-perturbed genes 302 in this study. We first obtained sets of canonical TOP genes and candidates containing previously 303 uncatalogued 5'TOP tracts, a subset of which have known TOP-containing homologues in the mouse 304 genome, from the comprehensive analysis of human transcription start sites performed by Yamashita et 305 al 25 . This yielded a total set of 1,626 TOP gene candidates: within this set, 237 candidates have mouse 306 homologues that are known TOP genes, and this subset overlaps substantially with the 83-member set 307 of canonical TOP genes identified (54/83 mouse homologues/canonical TOP). We found these TOP 308 candidates to behave similarly to canonical TOP genes in terms of perturbed RA. In the strip plots in 309 Figure 6A , TOP genes and candidates within the significant targets (FDR<0.05) of each drug on the plate 310 are color-coded, allowing comparison of their differential RA between conditions. 311
We then constructed a simple translational regulatory network from our riboPLATE-seq data and 312 overlaid it with these canonical and novel TOP genes ( Figure 6B) . We considered the genes 313 demonstrating significant reductions in RA due to treatment with PP242, MNK-i1, and BKM120 as the 314 positive translational targets of mTOR, PI3K, and MNK1, respectively, as these drugs are specific 315 inhibitors of these kinases. Here, we used a typical threshold for significance (FDR<0.05), but 316 additionally required target genes to have at least 20 average normalized read counts across all samples. 317
As expected, the targets of mTOR are enriched heavily for TOP genes and candidates. Nearly all known 318 TOP genes and candidates with mouse homology, as well as a significant majority of remaining TOP gene 319 candidates, are targets of mTOR. The largest fraction of each set is found in either the joint targets of 320 mTOR and PI3K or the exclusive targets of mTOR. The largest set of targets belongs to mTOR (228 321 exclusive/386 total), followed by PI3K (57 exclusive/213 total) and then MNK1 (21 exclusive/43 total), 322 and TOP genes and candidates comprise a larger fraction of mTOR targets than PI3K or MNK1 targets. 323
15
The set of targets common to all three kinases is also highly enriched for curated and novel TOP genes 324 (Fisher's exact test p=0.00006), suggesting a subset of TOP genes impacted by MNK1, though this three-325 way intersection is vastly smaller and less significantly-enriched for these genes than the two-way 326 intersection of mTOR and PI3K targets (Fisher's exact test p=6x10-24). Furthermore, the targets 327 exclusive to either MNK1 or PI3K are not significantly enriched for TOP genes and candidates (Fisher's 328 exact test p=0.760 and p=0.219, respectively) in contrast to the exclusive targets of mTOR (p=5x10-8). 329 Supplementary Table 2 details a more comprehensive statistical analysis of the network in Figure 6B Ribosome association is frequently used to infer translational activity. This can be measured by sucrose 337 gradient fractionation of intact RNA in polysome profiling, or of digested monosomes and their 338 ribosome-protected footprints in ribosome profiling. Translation efficiency, defined as the rate of 339 protein production per transcript, is approximated differently in these two methods. In polysome 340 profiling, it is calculated as the ratio of transcripts that sediment in "heavy" vs "light" fractions, similar to 341 the ratio of ribosome association in riboPLATE-seq. Ribosome profiling refines this measurement with its 342 focus on ribosome footprints, calculating instead a per-transcript ribosome occupancy with additional 343 information about position, regional density, and ribosome arrest 26 . riboPLATE-seq sacrifices the specific 344 positional information provided by ribosome profiling for a general measurement of ribosome 345 association, obtained by IP rather than sucrose gradient fractionation. With pooled library construction, 346 16 greater throughput is possible with riboPLATE-seq than with either ribosome profiling or polysome 347 profiling. 348 349 Though it is more scalable than ribosome profiling, riboPLATE-seq is not without limitations. The lack of 350 resolution of individual ribosome positions means the method cannot resolve location-specific effects, 351 such as the effect of ribosome association in 5' leader sequences on translation in downstream coding 352 sequences 7 . More generally, riboPLATE-seq is insensitive to translational regulation at the levels of 353 elongation or termination due to its inability to distinguish active from stalled ribosomes, a limitation 354 common to many ribosome-centric measurements 27 including ribosome profiling. 355
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In this study, we interrogated translational regulation in mitogenic signaling pathways in cancer cells. 357
Focal amplification of PDGFRA in TS-543 glioma neurospheres leads to constitutive activation of several 358 members of these pathways, including ERK, Akt, and PI3K 12 . We observed the expected results of mTOR 359 inhibition on translation with riboPLATE-seq, including decreased ribosome association with TOP genes, 360 and further clarified targets for the kinases PI3K and MNK1. We found PI3K to target a subset of the TOP 361 genes impacted by mTOR, without a strong impact on known TOP genes or candidate transcripts 362 separate from that shared with mTOR. This suggests the effect of PI3K on the TOP genes may be wholly 363 mediated by mTOR, consistent with the known organization of their signaling pathway. In contrast, 364 treatment with either the highly-specific MNK inhibitor MNK-i1 or the eIF4E inhibitor 4EGi-1 did not 365 significantly impact the TOP genes. Despite both drugs impacting the effector through which mTOR is 366 thought to mediate TOP gene translation, eIF4E, off-target effects of commonly-used MNK inhibitors in 367 past studies 22 may have overemphasized previous observations to this effect, and potential off-target 368 effects of 4EGi-1 28 complicate interpretation of its specific, eIF4E-dependent targets. 369 370 Pairwise combinations of inhibitors did not generate additive effects on ribosome association, instead 371 triggering what we interpreted as compensatory regulation and attenuating the strongest effects of 372 individual inhibitors. Surprisingly, combination treatment with PP242 and BKM120 attenuated their 373 individual targets the least, despite the seeming redundancy of these drugs targeting the same pathway. 374
Though still attenuated overall, a greater portion of the individual targets of PP242 and BKM120 were 375 enhanced by combination treatment. This might suggest that PI3K inhibition does not saturate inhibition 376 of its downstream effectors, including mTOR. These surprising findings highlight the utility of explicitly 377 testing combined perturbations and the need for scalable measurement strategies like riboPLATE-seq. 378
379

CONCLUSION 380
This study serves as a proof-of-concept for larger-scale perturbation screens of potential translational 381 regulators. Here, riboPLATE-seq revealed signatures of specific translational targets for kinases in related 382 signaling pathways. Our results are consistent with the known structure of these pathways, including the 383 previously established mechanism by which mTOR controls translation of the TOP motif-containing 384 genes. However, the majority of the ~500 known protein kinases remain unstudied at the level of 385 translational regulation. The technology described here could enable a more comprehensive screen of 386 protein kinases and/or RNA binding proteins, allowing inference of translational regulatory networks 387 and de novo identification of regulatory motifs important to these networks that might be validated by 388 high-resolution techniques like ribosome profiling and CLIP-seq. We anticipate that the ability to dissect 389 these networks at scale will advance our understanding of translational regulation and the design of 390 specific therapies for diseases involving aberrant translation. 391
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METHODS 393
Tissue Culture and Drug Treatment 394
We seeded TS-543 neursopheres (passage #11) on a 96-well plate (Corning, #3799) at a density of 7,500 395
cells per well (50,000 cells/mL) in 150uL NS-A complete medium (containing 10% v/v NeuroCult NS-A 396
Proliferation Supplement, 20ng/mL EGF, 10ng/mL bFGF, and 2ug/mL heparin) (STEMCELL Technologies 397 #05751). We incubated the plate of cells for 36 hours prior to the start of the experiment at 37°C and 5% 398 CO2 in a tissue culture incubator. We separately prepared stock solutions of PP242 (Tocris, #4257), 399 MNK-i1, NVP-BKM120 (Selleck, S2247), AZD8055 (Selleck, S1555), and 4EGi-1 (Tocris, #4800) in DMSO 400 vehicle (Sigma, #472301). After dilution with NS-A basal culture medium (without supplement, 401 cytokines, or heparin) (STEMCELL Technologies #05751), we administered the drugs or pure DMSO to 402 the experimental and control wells, respectively, in 1uL doses. Final concentrations were 50nM 403 AZD8055, 625nM PP242, 1μM BKM120, 100nM MNK-i1, and 50μM 4EGi-1, including in pairwise 404 combination-treated samples. Drug treatment proceeded for 6 hours in the tissue culture incubator 405 prior to lysis. 406
Cell Lysis 407
Following treatment, we centrifuged the plate of TS-543 for 7 minutes at 1800RPM on a Sorvall Legend 408 XTR at room temperature and removed supernatants by aspiration. Placing the plate on ice, we 409 resuspended the pelleted cells in each well in 30uL of polysome lysis buffer (20mM Tris-HCl, pH=7.4, 410 250mM NaCl, 15 mM MgCl2),0.1mg/mL cycloheximide, 0.5% Triton X-100, 1mM DTT, 0.5U/mL 411 SUPERase-In (ThermoFisher, AM2696), 0.024U/mL TURBO DNase (Life Technologies, AM2222), 1x 412 Protease Inhibitor (Sigma, P8340)), mixed 5 times by pipetting, and rested the plate on ice for 5 minutes. 413
We then centrifuged the plate for 5 minutes at 1400RPM at 4°C to remove bubbles before performing a 414 quick freeze-thaw, placing the plate first in a -80°C freezer and then resting at room temperature for 5 415 minutes each. Following an additional 10 minutes rest on ice, we viewed the plate under a microscope 416 to check the extent of cell lysis. At this point, we added standard RNA spike-ins (ERCC Spike-In Mix #1, 1 417 19 uL/well of 1:5000 diluted stock) (Life Technologies, #4456740) to half of the wells for spike-in depletion 418 experiments. We then prepared a new 96-well plate containing 3.5uL 2x TCL buffer (Qiagen, #1070498) 419 per well, to which we transferred 3.5uL of lysate (approximately 10% total volume). 420
Automated Pan-Ribosome Immunoprecipitation 421
To the remaining lysate, we added 1 uL of SUPERase-in (ThermoFisher, AM2696) and 1 uL of biotinylated 422 y10b antibody (ThermoFisher, MA516060) to each well, then sealed the plate and allowed it to incubate 423 while gently shaking for 4 hours at 4°C. During this incubation, we washed 500uL of Dynabeads MyOne 424 Streptavidin C1 streptavidin-coated magnetic beads (ThermoFisher, #65001) 3 times with polysome 425 wash buffer (20mM Tris-HCl (pH 7.4), 250mM NaCl, 15mM MgCl2, 1mM DTT, 0.1mg/mL cycloheximide, 426 0.05% v/v Triton X-100), using 1mL per wash and resuspending in 500uL. We added 5uL of washed 427 beads to each well, then incubated while gently shaking at 4°C for an additional hour. After this short 428 incubation, we placed the plate on a magnet, removed and reserved supernatants, and washed the 429 wells 3 times with 200uL per well of polysome wash buffer supplemented with 1uL/mL SUPERase-in on 430 the Biomek 4000 automated liquid handling system. 431
Following the final wash, we resuspended the beads in 15uL of ribosome release buffer (20mM Tris-HCl 432 (pH 7.4), 250mM NaCl, 0.5% Triton X-100, 50mM EDTA) per well. During a 15-minute incubation at 4C 433 on a Peltier module, with continuous pipet mixing on the Biomek 4000 in order to maximize elution, we 434 distributed 15uL of 2x TCL buffer to each well of a new 96-well plate. Finally, we replaced the sample 435 plate on the magnet and transferred eluants to the TCL-containing plate. 436
PLATE-seq Library Preparation and Sequencing 437
The plates of ribosome-associated and previously reserved total lysate in TCL buffer were submitted to 438 the Columbia Genome Center for processing by the previously-described PLATE-seq method of RNA-seq 439 library preparation 10 , which involves poly-A selection of transcripts, incorporation of sequence barcodes 440 20 in poly(T)-primed reverse transcription, and pooling for subsequent library preparation steps, generating 441 a single 3'-end RNA-seq library from each 96-well plate. We pooled total and ribosome-associated 442 PLATE-seq libraries and sequenced the combined libraries on the Illumina NextSeq 550 with a 75-cycle 443 high-output kit. With paired-end sequencing, the first read corresponds to the 3' end of a transcript, and 444 the second read contains the barcode identifying the library in which the read was obtained. 445
Ribosome Profiling and RNA Sequencing 446
We seeded TS-543 neurospheres in a 6-well plate at a starting density of 50,000 cells/mL in 2 milliliters 447 of NS-A complete medium per well, and allowed the plate to rest for 36 hours. After preparing PP242 448 and MNK-i1 solutions in DMSO as above, we treated two wells each with 625nM PP242, 1.0μM MNK-i1, 449 or DMSO vehicle for 6 hours in the tissue culture incubator. Following treatment, we transferred 450 samples to 15mL conical vials for centrifugation at 640 RCF for 7 minutes, then removed supernatants 451 and added 400 uL polysome lysis buffer (recipe above). After mixing by rapid pipetting, we transferred 452 samples to 1.8mL microcentrifuge tubes, rested them on ice for 5 minutes, and triturated by 5 passages 453 through a 23-gauge needle. Following a clarifying spin of 11K RCF for 10 minutes at 4C on a benchtop 454 centrifuge, we transferred supernatants to a new set of microcentrifuge tubes and discarded pellets. 455
Finally, we prepared ligation-free ribosome profiling and total RNA-seq libraries from these clarified 456 polysome lysates following the instructions provided with their respective kits (smarter-seq smRNA-seq 457 kit, Takara-Clontech; NEBnext Ultra-Directional II), augmented with our previously-published ligation-458 free ribosome profiling protocol 8 . We sequenced 6 ribosome profiling libraries or up to 12 RNA-seq 459 libraries in one NextSeq 550 high-output 75-cycle kit. 460
Both PLATE-seq and ligation-free ribosome profiling library preparation protocols are available on our 461 laboratory website 29 . 462
Read Alignment and Data Analysis 463 21
Using a custom pipeline, we first trim reads of trailing polyA sequence and adapters with fastx-clipper 30 464 (fastx-toolkit v0.0.14), then align the multiplexed reads to the hg19 assembly of the human genome and 465 known RNA spike-in sequences with STAR v2.4.0. We then demultiplex the aligned reads to their original 466 riboPLATE-or PLATE-seq libraries according to their barcodes (available in BarcodesHiSeq.txt). We use a 467 similar pipeline to process and align ribosome profiling and RNA sequencing libraries. Additional 468 processing steps are required for ribosome profiling in order to trim polyA tails and adapters with 469 fastx_trimmer 30 , then remove ribosomal RNA-aligned reads with bowtie2 31 (v2.1.0). We use 470 featureCounts 32 (from Subread v1.4.6) to count the number of fragments aligned to each gene in each 471 library, counting all exon-aligned reads as valid. 472
Definition of Gene Sets of Interest 473
As PLATE-and riboPLATE-seq depend on isolation of RNA by poly(T) pulldown, they can only be used to 474 measure polyadenylated transcripts. We defined a set of questionably-polyadenylated transcripts by the 475 union of the set of non-polyadenylated and variably-polyadenylated genes identified in a screen of 476 polyadenylation status across the transcriptome 33 . We removed these genes from consideration in our 477 study to leave only consistently polyadenylated transcripts. We additionally obtained a set of known 5' 478 terminal oligopyrimidine motif-containing genes (TOP genes), as well as novel TOP candidates with and 479 without known TOP-containing analogues in mice, from a comprehensive search of transcription start 480 sites 25 . 481
Regularized Logarithm Normalization and Outlier Removal 482
After subsetting the count matrices for all libraries to remove counts for reads aligned to non-483 polyadenylated and spike-in transcripts, we constructed an overall count matrix of all 192 libraries for all 484 96 samples. We loaded this matrix into DESeq2 with corresponding column data describing the sample 485 ID, library type (ribo or RNA PLATE-seq), and drug treatment for each library. We then used the 486 22 regularized logarithm function in DESeq2 with default parameters to obtain a variance-stabilized, log-487 scale transformation of raw counts for all libraries. 488
We used this transformed count matrix to perform two-dimensional principal component analyses (PCA) 489 in Python, utilizing the scikit-learn package for analysis and matplotlib for visualization. We removed a 490 total of 15 outliers from the PCA plots of ribosome-associated RNA, total RNA, and rlog-ribosome 491 association, which we defined as the log-difference between the two measurements (rlog(riboPLATE)-492 rlog(PLATE)). We then constructed a reduced matrix of raw counts corresponding to the remaining 81 493 samples (see Table 1 ) and again performed rlog normalization on this matrix in DESeq2. We used this 494 final matrix of rlog-normalized counts for non-outlier samples, as well as the raw count version of this 495 matrix, for RNA quality control and principal component analyses in Figures 2 and 3 , respectively. 496
Differential count analysis in DESeq2 497
We performed differential expression and differential ribosome association analyses using the DESeq2 498 package in R 34 . First we constructed a column data table identifying the sample ID, drug treatment, and 499 library type (riboPLATE vs PLATE) for each library. After loading this table and the raw count matrix for 500 non-outlier samples, we performed simultaneous analyses for all drug treatments vs DMSO-treated 501 controls using the following design formula: 502 design = ~condition + condition:ind.n + condition:type 503
In this design formula, condition refers to drug treatment status, type refers to riboPLATE-seq or PLATE-504 seq library preparation, and ind.n corresponds to sample ID nested within condition, in accordance with 505 the DESeq2 vignette 35 (section Group-specific condition effects, individuals nested within groups). Pairing 506 of riboPLATE-and PLATE-seq libraries from the same sample in this way allows DESeq2 to correct for 507 sample-to-sample noise while calculating group-wise effects of drug treatment. 508
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After setting PLATE-seq as the reference level for library type and DMSO as the reference level for drug 509 treatment condition, we executed the DESeq2 function using fitType=local, then retrieved results for 510 each drug treatment and comparison of interest. For differential ribosome association, we used function 511 calls of the following format: 512 res <-results(dds, name=paste0("typeribo.condition",cond)) 513
Where dds is the DESeqDataSet object and cond is any of the drug treatments. The interaction between 514 library type and drug treatment is equivalent to the calculation of ribosome association (RA). For 515 differential expression, we considered only changes in gene abundance between PLATE-seq libraries 516 independent of riboPLATE-seq. This required function calls of the following format: 517 res <-results(dds, name=paste0("condition",cond)) 518
Where dds is the DESeqDataSet object and cond is any of the drug treatments. This isolates the main 519 effect of drug treatment, defined across total RNA PLATE-seq libraries only. 520
For ribosome profiling and RNA sequencing, we followed a similar workflow, utilizing a design formula 521 without sample pairing: 522 design = ~condition + type + condition:type 523 where condition corresponds to drug treatment (MNKi1, PP242, or DMSO) and type corresponds to 524 RNA-seq vs ribosome profiling. We then set the base level of type to RNA and the base condition to 525 DMSO, and executed DESeq2 with fitType=local. Finally, we retrieved results specific to the 526 interaction effect, here equal to the calculated change in translation efficiency (TE) as a result of drug 527 treatment, with the following two function calls: 528 res_242 <-results(dds, name = "typeribo.conditionPP242") 529 res_MNK <-results(dds, name = "typeribo.conditionMNKi1") 530
Identification of Perturbed Gene Ontologies by Gene Set Enrichment Analysis 531
We constructed ranked lists for gene set enrichment analysis (GSEA) using the results of these 532 differential expression and ribosome association analyses. We first removed any gene with invalid 533 results reported by DESeq2 in any drug-vs-control comparison (i.e. genes with assigned p-value 'NA') 534 from consideration. Next, we created a ranked list of genes for each drug treatment, using each gene's 535 log-fold change in RA as a rank statistic. We then performed a preranked GSEA on the C5 collection of 536 gene ontology terms against these ranked lists, using the Preranked option in the GSEA-P desktop 537 application 36 , with default parameters and scoring method set to 'classic'. 538
Network Visualization 539
To create a basic network, we interpreted the abundant genes exhibiting highly significant reductions in 540 RA under treatment with kinase inhibitors (FDR<0.01, baseMean>=20) as positive targets of the kinases 541 in question. We loaded these gene sets into CytoScape 37 (v2.7.1) as individual networks for each kinase, 542 merged the three networks, and used the yFiles 38 Organic automatic layout to organize the resulting 543 merged network. We then color-coded the sets of canonical and novel TOP motif-containing genes 544 present in the network, based on the lists obtained from Yamashita et al 25 . 545
Data Visualization and Code 546
We generated plots and diagrams using matplotlib (v3.0.2) and Jupyter Notebook (v5.0.0) 39,40 . Our 547 analyses use NumPy 41 (v1.13.3) for data manipulation, SciPy 42 (v0.14.0) for statistical tests, scikit-learn 43 548 (v0.19.1) for PCA. We additionally generated strip plots and heatmaps using Seaborn 44 (v0.9.0) in 549 BKM120, and MNK-i1 treatments vs DMSO, calculated by DESeq2. In each, the Y axis corresponds to 632 significance and the X axis is effect size in terms of log-fold change in RA, with green dotted lines to 633 represent the thresholds of p=0.01 and lfcRA<-0.75. Genes meeting both thresholds are color-coded red 634 or blue, and represent the major inhibitory targets of these individual drugs. D-F) Volcano plots of the 635 three pairwise combinations of the drugs in A-C, highlighting the specific targets of the individual drugs. 636
In each, these specific targets have largely shifted down and rightward, indicating less significant and 637 smaller perturbation in RA of these targets in combination. G-I) Scatterplots comparing the effect under 638 single-drug treatment and the difference between combination and single-drug effects for the same 639 target sets from (A-C). These plots show the relationship between initial effect size under single drug 640 treatment and the degree of attenuation or amplification in this effect under combined treatment, 641 
